Qiagen shares trade at €45.02, below EQT's €46.50 takeover offer

A price pinned to the bid, not the business

At 11:15 CET on 4 November, Qiagen traded at €45.02 on Lang & Schwarz. The EQT XI fund has offered €46.50 in cash for every share [4].

That gap shows what the deal is worth to the market right now. It is €1.48 a share of doubt, spread over a closing expected in mid-2027 [4][5]. Holders can take the cash and wait. Or they can keep a stock while Qiagen's full-year 2026 outlook remains suspended for as long as the transaction is pending [4][13]. For customers and staff, the pitch is faster long-term investment under private ownership. Nothing is settled until regulators clear the bid and holders tender 50% of the capital plus one share [5][10]. Neither side has said what happens if that threshold fails.

Full third-quarter results were due at about 22:05 Frankfurt time on 4 November, 16:05 in New York [4][13].

A flat quarter, and no guidance to argue about

Qiagen said it would not hold an earnings call [4][13]. The preliminary numbers came out on 21 October, for the quarter ended 30 September [4][13]. Net sales were $548 million. Adjusted diluted earnings per share were $0.65. Both were unchanged on a reported and a constant-currency basis [4][13]. Qiagen has suspended its full-year 2026 outlook while the transaction runs. That leaves no forecast for analysts to test against the offer [4][13]. Nothing in the release changes the arithmetic of the bid.

There is no guidance left to argue about. That is the point.

What the deal actually changes

The offer values Qiagen at about €10.8 billion in enterprise value. That is roughly $12.1 billion at current exchange rates, including about $1.1 billion of net debt [5][10].

Qiagen's Supervisory Board and Managing Board unanimously recommend acceptance [5][7]. They argue that private ownership gives the diagnostics group more room to invest for the long term. Shareholders get certain cash value now [5][7]. Once the post-closing measures are done, the Frankfurt Stock Exchange and New York Stock Exchange listings are expected to terminate [10]. Qiagen serves more than 500,000 customers and employed about 5,400 people across more than 35 locations as of 30 September 2026 [10].

Those are the numbers a buyer is underwriting. They are also the numbers that stop arriving every quarter once the listings go.

The premium, and the reports that preceded it

Premiums depend on the base. The €46.50 offer is 40.3% above the XETRA closing price of €33.15 on 8 July 2026. That was the last trading day before market reports of private equity interest [5][6]. Against the three-month volume-weighted average price of €31.66 up to that date, it is 46.9% [5][10].

BioXconomy reported the same two percentages against figures given in dollars, $37.21 and $35.53, where the company release gives euros [8]. The percentages match. The currency in that write-up does not.

Before any of that, the market had already moved. Qiagen shares jumped more than 7% on Tuesday 20 October [3]. Bloomberg reported that EQT was in advanced talks with a binding offer above $50 a share, and that KKR had also bid [3]. Reports said the board would meet that week to weigh the offers. The people familiar with the talks cautioned they could still fall apart [3].

Who is paying, and with what

The bidder is Crown NL Bidco, a holding company. The EQT XI fund indirectly controls it [5][7].

Two sovereign investors sit alongside it. They are Luxinva, a subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe, a subsidiary of CPP Investments [5][7][10]. EQT XI has a target fund size of €23 billion and a hard cap of €24 billion [1]. After Qiagen, it will be 10-15% invested against that target [1]. The parent reported €354 billion in total assets under management as of 30 September 2026, of which €195 billion is fee-generating [1].

The financing is committed, and the offer is not conditional on it [10]. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are supporting the debt [10]. That removes one common reason for a bid to collapse. It does not remove the regulatory ones.

Downgrades, paperwork and the road to mid-2027

Analysts moved quickly once the price settled. JPMorgan cut Qiagen to Neutral from Overweight on 22 October. It trimmed its target to $52 from $55. Baird went to Neutral from Outperform a day later, holding $52 [13].

The paperwork followed. Qiagen filed the deal agreements with the US Securities and Exchange Commission on Form 6-K on 23 October [13]. That came two days after tender offer materials went in on Form SC 14D9-C. Crown NL Bidco filed its own on Form SC TO-C [13]. The tender offer has not yet commenced. The offer document needs approval before the acceptance period can begin [4].

Completion needs two things: acceptance from at least 50% of outstanding share capital plus one share, and customary regulatory clearances [5][10]. Closing is expected in mid-2027 [5][6]. Post-closing measures need 80% of votes cast. The boards retain discretion to proceed on support from a substantial majority of the shareholder base [8].

Qiagen has been here before. Thermo Fisher Scientific agreed in March 2020 to buy the company for $11.5 billion, and the deal lapsed in August 2020 [8].

The current offer is all cash, committed and recommended. The date to watch is mid-2027.